2023 | Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis | Liam, Chong Kin; Ahmad, Azura Rozila; Hsia, Te-Chun; Zhou, Jianying; Kim, Dong-Wan; Soo, Ross Andrew; Cheng, Ying; Lu, Shun; Shin, Sang Won; CHIH-HSIN YANG ; Zhang, Yiping; Zhao, Jun; Berghoff, Karin; Bruns, Rolf; Johne, Andreas; Wu, Yi-Long | Clinical cancer research : an official journal of the American Association for Cancer Research | 8 | 4 | |
2021 | The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study | Huang, Yen-Hsiang; Hung, Jen-Yu; Ko, How-Wen; Su, Po-Lan; Lai, Chun-Liang; Chang, Huang-Chih; Hsia, Te-Chun; Lin, Sheng-Hao; Wu, Kuan-Li; Yang, Cheng-Ta; Su, Wu-Chou; Chu, Yi-Chun; Wang, Chin-Chou; WEI-YU LIAO ; YEN-TING LIN ; Lin, Ching-Hsiung; Lin, Meng-Chih; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Lee, Mei-Hsuan; SUNG-LIANG YU ; CHAO-CHI HO ; Chang, Gee-Chen | Therapeutic advances in medical oncology | 3 | 2 | |